Barvarian Nordic has again delayed (slightly) when they expect to have the initial results of the Phase III clinical trial of Prostvac in the treatment of metastatic, castration-resistant prostate cancer (mCRPC).
A media release from the company (as one might expect) has placed the best possible “spin” on the announcement that data from the PROSPECT trial should now be expected in the fourth quarter of 2017 (i.e., some time between October and December).
The biotech news service FierceBiotech has a rather less positive perspective (which may also be more accurate) … but who knows?
Filed under: Drugs in development | Tagged: mCRPC, outcome, Prostvac, result, trial |
THE "NEW" PROSTATE CANCER INFOLINK 
Leave a Reply